Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The Protect Beneficiaries from Middlemen Act (H.R. 5197) amends Medicare Part D to cap beneficiary cost-sharing for a month’s supply of a covered Part D drug—after the deductible and before reaching the out-of-pocket threshold—at the drug’s average net price for the plan year (or, if lower, the pharmacy’s cash price). "Average net price" is defined as the average amount paid under the plan for that supply (including beneficiary cost sharing) minus rebates and other remuneration. The bill applies to plan years beginning on or after January 1, 2027, adds a conforming limit for low-income subsidy copayments, and requires a GAO report by January 1, 2029 on compliance, enforcement, and public disclosure/awareness recommendations.
Whether lowering point-of-sale cost sharing by tying it to average net price is an unambiguous win for beneficiaries (liberal says yes; conservatives worry about downstream cost-shifting).
Relative to its intended legislative type, this bill is a focused substantive amendment that clearly states a new legal limit on beneficiary cost sharing in Medicare Part D and supplies basic definitions and an effective date.
The Protect Beneficiaries from Middlemen Act (H.R. 5197) amends Medicare Part D to cap beneficiary cost-sharing for a month’s supply of a covered Part D drug—after the deductible and before reaching the out-of-pocket threshold—at the drug’s average net price for the plan year (or, if lower, the pharmacy’s cash price). "Average net price" is defined as the average amount paid under the plan for that supply (including beneficiary cost sharing) minus rebates and other remuneration.
The bill applies to plan years beginning on or after January 1, 2027, adds a conforming limit for low-income subsidy copayments, and requires a GAO report by January 1, 2029 on compliance, enforcement, and public disclosure/awareness recommendations.
On substance the bill is a targeted reform aimed at reducing beneficiary cost-sharing distortions and could garner public sympathy, but it alters entrenched payment flows in Medicare Part D and lacks detailed administrative enforcement language and cost offsets. Those features raise opposition from stakeholders and complicate legislative negotiations, making enactment plausible but not likely without significant compromise or incorporation into a larger package.
Relative to its intended legislative type, this bill is a focused substantive amendment that clearly states a new legal limit on beneficiary cost sharing in Medicare Part D and supplies basic definitions and an effective date. It provides a mandated GAO report to review compliance and enforcement. The statutory language gives a simple rule but omits many practical implementation details and resource or enforcement provisions that would typically accompany a policy with cross-cutting programmatic effects.
Whether lowering point-of-sale cost sharing by tying it to average net price is an unambiguous win for beneficiaries (liberal says yes; conservatives worry about downstream cost-shifting).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether lowering point-of-sale cost sharing by tying it to average net price is an unambiguous win for beneficiaries (liberal says yes; conservatives worry about downstream cost-shifting).
A mainstream liberal would likely view the bill favorably as a policy that reduces out-of-pocket costs for Medicare Part D enrollees and weakens the ability of middlemen (e.g., PBMs) to leave beneficiaries paying prices based on gross list prices rather than net prices after rebates.
They would see this as a consumer protection and equity measure that particularly helps people who are on fixed incomes and who face high pre-catastrophic drug costs.
They may acknowledge possible unintended market consequences but generally support directing savings from rebates to lower point-of-sale cost sharing.
A centrist or moderate would see the bill as a targeted consumer-protection reform with plausible benefits for beneficiaries but with notable tradeoffs and implementation questions.
They would appreciate that it attempts to align point-of-sale costs with net prices but would be cautious about unintended consequences for premiums, federal spending, and market incentives.
They would favor careful monitoring, clear definitions, and enforcement mechanisms before full endorsement.
A mainstream conservative would likely view the bill skeptically as federal interference in private contract and market negotiation mechanisms among plans, pharmacies, PBMs, and manufacturers.
They would be concerned that legislating cost-sharing based on a computed "average net price" disrupts rebate negotiations and could raise premiums, shift costs to taxpayers, or reduce incentives for price competition.
They would emphasize potential administrative complexity and unintended fiscal consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is a targeted reform aimed at reducing beneficiary cost-sharing distortions and could garner public sympathy, but it alters entrenched payment flows in Medicare Part D and lacks detailed administrative enforcement language and cost offsets. Those features raise opposition from stakeholders and complicate legislative negotiations, making enactment plausible but not likely without significant compromise or incorporation into a larger package.
The bill has not accumulated any surfaced votes yet.
Whether lowering point-of-sale cost sharing by tying it to average net price is an unambiguous win for beneficiaries (liberal says yes; con…
On substance the bill is a targeted reform aimed at reducing beneficiary cost-sharing distortions and could garner public sympathy, but it…
Relative to its intended legislative type, this bill is a focused substantive amendment that clearly states a new legal limit on beneficiary cost sharing in Medicare Part D and supplies basic definitions and an effectiv…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.